Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELIVERS Phase 2 study of topical diacerein 1% ointment in epidermolysis bullosa simplex
NL-OMON47706Phase 2Completed
- Sponsor
- Castle Creek Biosciences
- Start
- Nov 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of diacerein in epidermolysis bullosa simplex (EBS) (2 arms), sponsored by Castle Creek Biosciences. Primary endpoint: Primary efficacy endpoint. Started Nov 2017; status: completed.
02
Drugs
diacerein
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on NL-OMON47706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47706.